The goal of continuing medical education (CME) is professional growth and improved patient care. We sought to determine if a curriculum of online continuing medical education (CME) activities could improve the clinical knowledge and confidence of diabetologists and endocrinologists (D/Es) related to use of mineralocorticoid receptor antagonists (MRAs) in the management of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D). The online CME curriculum consisted of 5 online activities. Of these, 4 used repeated pairs pre-/post-assessment study design was used and McNemar’s test (P <.05 is considered significant) to assess educational effect. The activities launched in 2020 and data were collected for up to 12 weeks. The education reached over 19,000 physicians, including 6,000 D/Es.

Overall, knowledge improved by 9% among D/Es (N=1,111, P<.001) Specific improvements: • 8% relative increase in knowledge related to the role of MRAs in treatment of CKD in T2D (P<.01) • 16% relative increase in knowledge related to the mechanism of action (MOA) of MRAs for CKD in T2D (P<.01) • 9% relative increase in knowledge related to identifying CKD in patients with T2D (P<.01)

Of the D/Es who were included, 34% had a measurable increase in confidence, and among those the average level of confidence increased 50%.

While this curriculum demonstrated success in educating on this topic, some gaps still remain after education. On average, 22% of the questions assessing knowledge on the MOA of MRAs in managing CKD in T2D and 29% of the questions assessing knowledge related to the role of MRAs in the management of CKD in T2D were still incorrectly answered after education, demonstrating a need for more education in these areas.

Disclosure

A. Larkin: None. K. L. Hanley: None. A. Le: None.

Funding

Bayer AG

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.